Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II pharmacogenetic study of high-dose irinotecan FOLFIRI in metastatic colorectal cancer by UGT1A1 genotype
2012-000221-42Phase 2Active
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Mar 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Overall objective response rate. Started Mar 2012; status: active.
02
Drugs
irinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2012-000221-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000221-42.